<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We treated six patients with primary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with <z:chebi fb="0" ids="2636">amifostine</z:chebi> (200 mg/m(2) i.v./three times a week for three consecutive weeks) </plain></SENT>
<SENT sid="1" pm="."><plain>Neutrophil counts were more frequently increased than platelet and reticulocyte counts, but no reduction of the transfusion requirement was observed </plain></SENT>
<SENT sid="2" pm="."><plain>Significant reduction of the marrow blasts was observed in one case of refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess of blasts </plain></SENT>
<SENT sid="3" pm="."><plain>In vitro stimulation of haematopoiesis was observed in five cases </plain></SENT>
<SENT sid="4" pm="."><plain>The apoptotic rate of marrow cells was significantly diminished even after the first course </plain></SENT>
<SENT sid="5" pm="."><plain>Our findings show fairly good clinical and biological response to <z:chebi fb="0" ids="2636">amifostine</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>